Collaboration to Advance Molecular Imaging Technology
|
By HospiMedica staff writers Posted on 20 Oct 2003 |
|
A collaboration to develop a cost-effective, readily accessible molecular imaging technology that can help more clinics and hospitals diagnose cancer has been announced by Philips Medical Systems (Best, The Netherlands) and CellPoint, L.L.C. (Englewood, CO, USA).
The collaboration will combine Cellpoint's novel diagnostic imaging agent and the nuclear medicine camera of Philips to make functional imaging readily available. The agreement will utilize CellPoint's ethylenedicysteine drug conjugate technology (EC technology), a delivery system that links tissue-specific ligands (hormones, proteins, peptides) or pharmaceutical compounds to radioisotopes for cancer diagnosis and treatment. Using clinical trial data, Philips will further develop and refine imaging techniques for SKYlight, its gantry-free nuclear camera, to determine requirements for the highest possible image quality and quantitative information about patients' disease.
The companies will collaborate on CellPoint's first imaging agent, Tc-99m-EC-deoxyglucose. EC technology allows the deoxyglucose to be labeled with the radioisotope technetium-99m (Tc-99m). The agent will target tumors, while single positron emission computed tomography (SPECT) cameras will image them, including Philips' nuclear medicine cameras. Tumors absorb more glucose than surrounding tissue, so when a cancer patient is injected with this chemically linked agent, active tumors will absorb both the glucose and the radioisotope.
"Philips has outstanding SPECT technology, and we're thrilled to strategically align ourselves with them to help advance molecular imaging agents, enabling more facilities to conduct cancer screening,” said Greg Colip, CEO of CellPoint. The company obtained the worldwide license to EC technology from the University of Texas M.D. Anderson Cancer Center (Houston, USA).
Related Links:
CellPoint
Philips Medical
The collaboration will combine Cellpoint's novel diagnostic imaging agent and the nuclear medicine camera of Philips to make functional imaging readily available. The agreement will utilize CellPoint's ethylenedicysteine drug conjugate technology (EC technology), a delivery system that links tissue-specific ligands (hormones, proteins, peptides) or pharmaceutical compounds to radioisotopes for cancer diagnosis and treatment. Using clinical trial data, Philips will further develop and refine imaging techniques for SKYlight, its gantry-free nuclear camera, to determine requirements for the highest possible image quality and quantitative information about patients' disease.
The companies will collaborate on CellPoint's first imaging agent, Tc-99m-EC-deoxyglucose. EC technology allows the deoxyglucose to be labeled with the radioisotope technetium-99m (Tc-99m). The agent will target tumors, while single positron emission computed tomography (SPECT) cameras will image them, including Philips' nuclear medicine cameras. Tumors absorb more glucose than surrounding tissue, so when a cancer patient is injected with this chemically linked agent, active tumors will absorb both the glucose and the radioisotope.
"Philips has outstanding SPECT technology, and we're thrilled to strategically align ourselves with them to help advance molecular imaging agents, enabling more facilities to conduct cancer screening,” said Greg Colip, CEO of CellPoint. The company obtained the worldwide license to EC technology from the University of Texas M.D. Anderson Cancer Center (Houston, USA).
Related Links:
CellPoint
Philips Medical
Gold Member
12-Channel ECG
CM1200B
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Bipolar Coagulation Generator
Aesculap
New
Antimicrobial Mat
MULTIMAT
Latest Business News
- Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies
- Medtronic Partners with Corsano to Expand Acute Care & Monitoring Portfolio in Europe
- Expanded Collaboration to Transform OR Technology Through AI and Automation
- Becton Dickinson to Spin Out Biosciences and Diagnostic Solutions Business
- Boston Scientific Acquires Medical Device Company SoniVie
- 2026 World Hospital Congress to be Held in Seoul
- Teleflex to Acquire BIOTRONIK’s Vascular Intervention Business
- Philips and Mass General Brigham Collaborate on Improving Patient Care with Live AI-Powered Insights
- Arab Health 2025 Celebrates Landmark 50th Edition
- Boston Scientific Acquires Medical Device Company Intera Oncology
- MEDICA 2024 to Highlight Hot Topics of MedTech Industry
- Start-Ups To Once Again Play Starring Role at MEDICA 2024
- Boston Scientific to Acquire AFib Ablation Company Cortex
- Hologic Acquires Gynesonics to Strengthen Existing Gynecological Surgical Business
- Smith+Nephew and JointVue Partner on Ultrasound Preoperative Planning in Robotics-Assisted Surgery
- Stryker Completes Acquisition of NICO Corporation
Channels
Critical Care
view channel
Implantable Device Could Save Diabetes Patients from Dangerously Low Blood Sugar
For individuals with Type 1 diabetes, hypoglycemia (low blood sugar) presents a life-threatening threat, particularly when glucose levels drop too low, which can result in seizures, coma, or even death.... Read more
New Prostate Screening Device Could Replace Traditional Examination Method
Prostate cancer is a leading health concern, with one in seven men being diagnosed with the disease. Early detection is critical for improving patient outcomes, but traditional diagnostic methods, such... Read more
Surgical Techniques
view channel
Fluorescent Imaging Agent ‘Lights Up’ Nerves for Better Visualization During Surgery
Surgical nerve injury is a significant concern in head and neck surgeries, where nerves are at risk of being inadvertently damaged during procedures. Such injuries can lead to complications that may impact... Read more
LED-Based Imaging System Could Transform Cancer Detection in Endoscopy
Gastrointestinal cancers remain one of the most common and challenging forms of cancer to diagnose accurately. Despite the widespread use of endoscopy for screening and diagnosis, the procedure still misses... Read more
Patient Care
view channel
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
VR Training Tool Combats Contamination of Portable Medical Equipment
Healthcare-associated infections (HAIs) impact one in every 31 patients, cause nearly 100,000 deaths each year, and cost USD 28.4 billion in direct medical expenses. Notably, up to 75% of these infections... Read more
Portable Biosensor Platform to Reduce Hospital-Acquired Infections
Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds
Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read moreHealth IT
view channel
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read more
